Friday, May 09, 2025 4:43:56 PM
Started to Nibble on some madrigal options late 2025 holding my core position from the 70.00's AKRO shit data makes MDGL more valuable.
Interesting Madrigal and Sagimet doing a single pill combo of their two drugs soon. Does Madrigal take out Sagimet or does a bigger player show up Bill Sibold Deeper pocket BP like LLY Gilead Novo or Novartis can scoop up on SGMT and not even Flinch they have the best looking oral in the space that works wonders with ThR B and GLP1 like Ozempic in combos a blockbuster stand alone first Line F2 F3 & F4 and a blockbuster for combos with GLp1 42% fibrosis reduction vs 0% in placebo.
$MDGL
Interesting Madrigal and Sagimet doing a single pill combo of their two drugs soon. Does Madrigal take out Sagimet or does a bigger player show up Bill Sibold Deeper pocket BP like LLY Gilead Novo or Novartis can scoop up on SGMT and not even Flinch they have the best looking oral in the space that works wonders with ThR B and GLP1 like Ozempic in combos a blockbuster stand alone first Line F2 F3 & F4 and a blockbuster for combos with GLp1 42% fibrosis reduction vs 0% in placebo.
$MDGL
Recent MDGL News
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/04/2026 08:05:00 PM
- Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 • GlobeNewswire Inc. • 06/03/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/01/2026 11:49:09 PM
- Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 10:01:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 08:34:43 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/21/2026 08:05:00 PM
- Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk • GlobeNewswire Inc. • 05/20/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 09:36:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/18/2026 09:34:52 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 04:37:40 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/07/2026 08:05:00 PM
- Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion • IH Market News • 05/06/2026 02:46:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 01:04:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:06:34 AM
- Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline • GlobeNewswire Inc. • 05/05/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:22:15 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 08:17:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:13:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:05:35 PM
- Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/07/2026 08:05:00 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
